Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Bradykinesia Market Through 2029?

The market size for bradykinesia has experienced fast growth recently. Forecasted to expand from $3 billion in 2024, it is projected to reach $3.41 billion in 2025, boasting a compound annual growth rate (CAGR) of 13.6%. This historical growth can be linked to the rising number of clinics addressing movement disorders, an increasing prevalence of post-stroke motor complications, the presence of inherited neurodegenerative conditions, a surge in clinical trials concerning therapies related to bradykinesia, as well as significant improvements in healthcare infrastructure.

Expectations are high for considerable expansion in the bradykinesia market size in the coming years. The market is anticipated to swell to $5.64 billion by 2029, bolstered by a compound annual growth rate (CAGR) of 13.4%. Factors contributing to this steep rise during the forecast period include escalating incidences of parkinson’s disease worldwide, a rise in neurological disorders, an aging demographic predisposed to neurodegenerative issues, growing consciousness and early detection of bradykinesia, and burgeoning diagnostic capabilities in developing economies. Prevailing trends during the projection period encompass advancements in neurostimulation devices, the emergence of innovative drug administration modes, the deployment of wearable technology for movement tracking and symptom monitoring, the proliferation of telehealth and distant neurology consultations, and the evolution of gene therapy focused on motor dysfunction.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24487&type=smp

What Market Forces Are Driving The Bradykinesia Sector In 2025 And Beyond?

The growth of the bradykinesia market is expected to be fueled by the rising occurrence of neurological disorders in the future. Nervous system diseases, which affect the brain, nerves, or spinal cord and potentially disrupt cognition, sensation, movement, or other bodily functions, are becoming increasingly prevalent, largely due to global aging. As brain changes related to age increase the susceptibility to neurological conditions, the number of these disorders continues to grow. This surge, in turn, drives the need for treatments for bradykinesia, a condition common to many neurological disorders that results in reduced or slow movement, necessitating therapies to enhance motor function. The American Parkinson Disease Association (APDA), a US-based advocacy group, projected in January 2023 that Parkinson’s disease alone is expected to impact 1.3 million individuals by 2030, further highlighting the steady increase in diagnosed cases. As such, the proliferating occurrences of neurological disorders are set to promote the expansion of the bradykinesia market.

How Is The Global Bradykinesia Market Categorized By Segments?

The bradykinesia market covered in this report is segmented –

1) By Combination Therapy: Mono-Therapy, Combination Therapy

2) By Disease Severity: Early-Stage Parkinson’s, Advanced-Stage Parkinson’s

3) By Symptom Management: Bradykinesia, Tremors, Rigidity

Subsegments:

1) By Mono-Therapy: Levodopa, Dopamine Agonists, MAO-B Inhibitors, Anticholinergics, Amantadine

2) By Combination Therapy: Levodopa And Carbidopa, Levodopa And COMT Inhibitors, Dopamine Agonists And MAO-B Inhibitors, Levodopa And MAO-B Inhibitors, Triple Therapy

What Long-Term Trends Are Likely To Affect The Bradykinesia Market?

Leading firms in the bradykinesia market are concentrating on producing novel solutions like sublingual therapies that ease administration, particularly for patients who find swallowing pills challenging. Sublingual therapies require a medication to be placed under the tongue where it is quickly absorbed into the bloodstream through mucous membranes for immediate effect. For example, in March 2023, Parkinson’s disease therapeutics provider BIAL, based in Portugal, introduced KYNMOBI (apomorphine hydrochloride) for the as-and-when-required treatment of OFF episodes in Parkinson’s disease. These OFF episodes in Parkinson’s disease are characterized by the reoccurrence or escalation of symptoms such as bradykinesia, tremor, and rigidity when standard medications stop being effective. The apomorphine hydrochloride sublingual film formulation presents a quick-acting, on-demand solution that melts beneath the tongue. As a type of non-ergoline dopamine agonist, it aids in the management of sudden motor symptom fluctuations. This treatment is typically tolerated well and allows more consistent control over symptoms during OFF periods.

Which Firms Are Considered Leaders In The Bradykinesia Market Space?

Major companies operating in the bradykinesia market are AbbVie Inc., Novartis AG, Medtronic Plc, Eli Lilly and Company, Otsuka Pharmaceutical Co. Ltd., Biogen Inc., Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Lundbeck AS, Amneal Pharmaceuticals Inc., Orion Corporation, Acadia Pharmaceuticals Inc., Acorda Therapeutics Inc., Denali Therapeutics Inc., Adamas Pharmaceuticals, Impel NeuroPharma, Annovis Bio Inc., BlueRock Therapeutics LLC, NeuroDerm Ltd., Cerevance LLC, Sage Therapeutics, Anavex Life Sciences Corp., Inhibikase Therapeutics Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bradykinesia-global-market-report

What Role Do Regional Policies And Investments Play In Bradykinesia Market Expansion?

North America was the largest region in the bradykinesia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bradykinesia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24487&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model